Niagen Bioscience, Inc. (NAGE) stock analysis
Close on Nov 12, 2026Market cap $168.93MP/E 17.8Yield –
StockData Score
Prices as of Nov 11, 2026How the score works
Mixed14 of 30 checks passed
Niagen Bioscience passes 14 of the 30 checks behind our score; 10 could not be run for lack of data and count as not passed. Each dot in the shape is one check — hover it for the numbers.
- Valuation
- 3/6
- Growth
- 1/6
- Past performance
- 4/6
- Financial health
- 6/6
- Dividend
- 0/6
What stands out
Trading below fair value
The share price of $2.10 is below our fair value estimate of $2.47.
Return on capital over 10%
Return on invested capital was 44.3%, above the 10% that usually covers the cost of capital.
No debt
Niagen Bioscience has no borrowings on its latest balance sheet.
Revenue growing 10%+ a year
Revenue grew 21.6% a year over the last three fiscal years.
What to watch
Margin of safety under 20%
The price is 15.3% below fair value, less than the 20% cushion we look for.
Return on equity under 15%
Return on equity was 13.3% over the last twelve months and averaged -26.7% over five years; we look for 15% on both.
Guidance lowered
Niagen Bioscience lowered its 2026 Full Year General & administrative outlook on May 6, 2026.
Growing slower than the industry
Revenue grew -1.9% over the last twelve months; the Drugs median is 8.0%.
Valuation3/6
P/E against its history
Not enough price and earnings history to compare.
P/E below the industry
Niagen Bioscience's P/E of 17.5 is below the Drugs median of 25.1.
EV/EBITDA against its history
Needs positive EBITDA and price history.
P/B below the industry
Niagen Bioscience's price-to-book of 2.00 is below the Drugs median of 2.29.
Trading below fair value
The share price of $2.10 is below our fair value estimate of $2.47.
Margin of safety under 20%
The price is 15.3% below fair value, less than the 20% cushion we look for.
Growth1/6
Revenue growing 10%+ a year
Revenue grew 21.6% a year over the last three fiscal years.
EPS growth over 3 years
Needs positive EPS three years ago and today.
Earnings acceleration
Needs positive net income now, a year ago and five years ago.
Growing slower than the industry
Revenue grew -1.9% over the last twelve months; the Drugs median is 8.0%.
Guidance lowered
Niagen Bioscience lowered its 2026 Full Year General & administrative outlook on May 6, 2026.
Gross margin slipping
Gross margin was 63.9% over the last twelve months, against 63.9% a year earlier.
Past performance4/6
Return on equity under 15%
Return on equity was 13.3% over the last twelve months and averaged -26.7% over five years; we look for 15% on both.
Return on capital over 10%
Return on invested capital was 44.3%, above the 10% that usually covers the cost of capital.
Return on equity above the industry
Niagen Bioscience's return on equity of 13.3% is above the Drugs median of -58.9%.
Earnings over 5 years
Needs positive net income five years ago and in the latest year.
Net margin above its 5-year average
Net margin was 8.4% over the last twelve months, against a 5-year average of -9.4%.
Net margin above the industry
Niagen Bioscience's net margin of 8.4% is above the Drugs median of -53.0%.
Financial health6/6
No debt
Niagen Bioscience has no borrowings on its latest balance sheet.
Debt not rising
With no debt today, leverage cannot have risen.
Debt covered by cash flow
There is no debt to cover.
Interest well covered
No meaningful interest expense to cover.
Short-term assets cover short-term debts
Current assets are 5.93 times current liabilities.
Low bankruptcy risk
The Altman Z-score is 4.03; above 3 is the safe zone and below 1.8 the distress zone.
Dividend0/6
No dividend
Niagen Bioscience has not paid a dividend in the last twelve months.
Yield against Treasuries
No dividend.
Yield against the market
No dividend.
Dividend stability
No dividend.
Earnings cover
No dividend.
Cash-flow cover
No dividend.
Fair value
How we estimate itOur estimate per share
$2.47
The share price is 15% below this estimate.
| Method | Multiple used | Own 5Y median | Industry median | Value per share | Weight |
|---|---|---|---|---|---|
| P/E | 25.1× | – | 25.1× | $3.01 | 40% |
| EV/EBITDA | 17.1× | – | 17.1× | $1.91 | 35% |
| P/B | 3.8× | 5.3× | 2.3× | $3.98 | 10% |
| Earnings power | 10.1% cost of equity | – | – | $1.36 | 15% |
| Fair value | $2.47 | 100% | |||
Valuation over time
Using the earnings and balance sheet published at each date, not today's.
- P/E at month end
- Drugs median 25.1
An estimate from reported numbers and market multiples, not a price target or investment advice. It can be far off for companies whose profits are about to change sharply.
Market risk
From the past year of daily prices.
Liquidity
High risk
- Average value traded per day
- $1.49M
- Value traded per 1% price move
- $588.88K
Downside
High risk
- Typical loss in a bad month
- 25.4%
- Volatility (annualized)
- 51%
- Sharpe ratio, 1 year
- -1.48
- Beta to the S&P 500 (5Y)
- 1.05
Typical bad-month loss, week by week
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
Operating margin
Net margin
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +29.9% | +21.6% | +16.9% | +21.9% | |
| Gross profit | +35.1% | +24.8% | +18.7% | +27.1% | |
| Operating income | +110.7% | – | – | – | |
| Net income | +103.3% | – | – | – | |
| EPS, diluted | +81.8% | – | – | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -38.4% | -108.1% | 28.3% | |
| Return on assets | -15.2% | -50.7% | 19.9% | |
| Current ratio | 1.77 | 1.96 | 4.86 | |
| Interest coverage | -8.7× | -279.6× | – | |
| Inventory turnover | 1.4× | 2.1× | 3.1× | |
| Capex to revenue | 6.9% | – | – | |
| Diluted shares | 37M | 61M | 85M |
Cash use needs five years of cash flow figures
Niagen Bioscience does not report operating cash flow and capital expenditure for each of the last five fiscal years.
DuPont analysis
Return on equity split into margin, efficiency and leverage
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | 13.4% | 1.48× | 1.42× | 28.3% |
| FY2024 | 8.6% | 1.62× | 1.65× | 22.9% |
| FY2023 | -5.9% | 1.53× | 1.91× | -17.3% |
| FY2022 | -23.0% | 1.29× | 1.85× | -54.8% |
| FY2021 | -40.2% | 1.40× | 2.00× | -112.7% |
| FY2020 | -33.6% | 1.51× | 2.13× | -108.1% |
| FY2019 | -69.4% | 1.12× | 1.73× | -135.0% |
| FY2018 | -105.6% | 0.60× | 1.30× | -82.2% |
| FY2017 | -53.7% | 0.51× | 1.29× | -35.7% |
| FY2016 | -13.5% | 1.13× | 2.52× | -38.4% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
- ProfitableNet income above zero$17.38M
- Cash generatingOperating cash flow above zero$13.50M
- Return on assets improvedROA up on the prior year15.6% → 25.5%
- Earnings backed by cashOperating cash flow above net income$13.50M vs $17.38M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose3.57 → 4.86
- No dilutionShare count did not rise78M → 85M
- Gross margin improvedGross margin up on the prior year61.84% → 64.28%
- More efficientAsset turnover rose1.81 → 1.90
See a number that looks wrong?